An interventional study of Connected device named "Leo" from Ludocare society in Cystic Fibrosis in Children and Chronic Disease, sponsored by Centre Hospitalier de Saint-Brieuc. Status unknown at 2 sites in France. Open to participants aged 3 Years to 11 Years. Per ClinicalTrials.gov, last updated 2021-01-22.
Sponsored by Centre Hospitalier de Saint-Brieuc · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study will be conducted over a 6 months period. For the first three months, the child will be accompagned with a connected companion. After this period, the companion will be removed for three months in oder to prove this companion could improve treatment adherence for children suffering from cytolisis fibrosis.
This study will be conducted at the University Hospital Center of Rennes and Hospital Center of Saint-Brieuc.
In developed countries, chronic diseases with long-term therapy adherence is about 50%, according to the WHO report, and the adherence rate for regular intake of preventive therapies decreases to 28%.
For cystic fibrosis, rates are not much higher. Optimistic articles report an average compliance rate of 60%. Other articles report a rate of 50% which varies according to the age of the patient, the intake treatment complexity and burdensome drug treatment (physiotherapy achieves the lowest adherence with 38%), the disease understanding and the interest of treatment persuasion. Low adherence can also be the result of incorrect use of administration devices, for example for inhaled treatments. Technical errors are very frequent and affect around 30% of patients.
Families with children suffering from cystic fibrosis need daily support. Health professionals need to relay their recommendations at home. This is why new and funny tools dedicated to children with chronic illnesses are needed.
This trial will study the impact of connected companion named LEO® created by Ludocare company.
Study will be conducted as :
782 studies on the registry are indexed under Chronic Disease; 144 are open to participants now.
This study's planned enrollment of 30 is below the median of 140 across 582 interventional studies indexed under Chronic Disease.
Browse Chronic Disease studies →Centre Hospitalier de Saint-Brieuc is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Connected device for three months period to support children care
Device: Connected device named "Leo" from Ludocare society
Connected device named "Leo" from Ludocare society will be allocated to each child for three-months period. During this time, child will be helped to take all of his medication and specific care by this connected device.
Evaluate therapeutic adherence of children with cystic fibrosis aged 3 to 11 years with help of a connected medical companion
The main evaluation criterion will be the overall compliance of the cohort in percentage terms. These data from connected companion will be refined for each type of treatment: pancreatic extracts, inhaled treatments, CFTR modulator, antibiotics, vitamins, laxative treatment, antacids, bile acids, food supplements, physiotherapy. For each treatment, the data "take" or "not take" will be treated by device and provide for statistical analysis in percentage. Each percentage will be grouped in global percentage will be therapeutic adherence all over study.
Time frame: Through study completion, up to 6 months
Study of the reasons of low compliance or difficulties in taking the treatments
Questionnaire for parents with up to 15 treatments which provide the major difficulties (to be indicated in order, from the most difficult to the simplest, with checked answers; no specific scale available)
Time frame: At the inclusion
Assess the psycho-social impact of treatment and illness
Questionnaire for parents on child's behaviours in regard to taking treatment and illness (scale from 0 to 10, , highers scores mean better outcome)
Time frame: At the inclusion
Assess child's autonomy regarding his treatments
Reporting in connected device
Time frame: 3 months
Assess the intake treatments quality
Questionnaire for parents on difficulties frequency with checked answers (no specific scale available)
Time frame: At the inclusion
Evaluate any negative impacts associated with the use of the robot
Questionnaire for parents on difficulties linked to the use of the robot with scale from 0 to 10, highers scores mean better outcome, and open ended questions (no specific scale is available)
Time frame: 3 months
Evaluate any negative impacts associated with the use of the robot
Questionnaire for parents on difficulties linked to the use of the robot with scale from 0 to 10, highers scores mean better outcome, and open ended questions (no specific scale is available)
Time frame: 4 to 6 months
Assess the psycho-social impact of treatment and illness
Questionnaire for children on his relation to his illness and his treatments (Color gradient scale with expressive smiley : red (sad), orange (a little bit sad), yellow (neutral), light green (good), dark green (very good)
Time frame: at the inclusion
Assess the psycho-social impact of treatment and illness
Questionnaire for children on his relation to his illness and his treatments (Color gradient scale with expressive smiley : red (sad), orange (a little bit sad), yellow (neutral), light green (good), dark green(very good)
Time frame: 3 months
Assess the psycho-social impact of treatment and illness
Questionnaire for children on his relation to his illness and his treatments (Color gradient scale with expressive smiley : red (sad), orange (a little bit sad), yellow (neutral), light green (good), dark green(very good)
Time frame: 4 to 6 months
Study of the reasons of low compliance or difficulties in taking the treatments
Questionnaire for parents with up to 15 treatments which provide the major difficulties (to be indicated in order, from the most difficult to the simplest, with checked answers; no specific scale available)
Time frame: 3 months
Assess the psycho-social impact of treatment and illness
Questionnaire for parents on child's behaviours in regard to taking treatment and illness (scale from 0 to 10, , highers scores mean better outcome)
Time frame: 3 months
Assess the intake treatments quality
Questionnaire for parents on difficulties frequency with checked answers (no specific scale available)
Time frame: 3 months
Study of the reasons of low compliance or difficulties in taking the treatments
Questionnaire for parents with up to 15 treatments which provide the major difficulties (to be indicated in order, from the most difficult to the simplest, with checked answers; no specific scale available)
Time frame: 4 to 6 months
Assess the psycho-social impact of treatment and illness
Questionnaire for parents on child's behaviours in regard to taking treatment and illness (scale from 0 to 10, , highers scores mean better outcome)
Time frame: 4 to 6 months
Assess child's autonomy regarding his treatments
Reporting in connected device
Time frame: 4 to 6 months
Assess the intake treatments quality
Questionnaire for parents on difficulties frequency with checked answers (no specific scale available)
Time frame: 4 to 6 months
Plan to share: No
Started Jan 2021 (actual). Primary completion is estimated for Jun 2021, 5 months after the start.
Of 319 non-industry interventional studies with no phase under Chronic Disease, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 33. This study's planned 5 months is below that.
Counting every sponsor, half of 329 studies reached it within 21 months; a quarter within 11 and three quarters within 33.
Chronic Disease covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier de Saint-Brieuc